Sign Out
Hypersensitivity to the active substance or to any of the excipients listed in Description.
Patients with bleeding disorders that are not under adequate control.
Pre-treatment MRI findings of prior intracerebral haemorrhage, more than 4 microhaemorrhages, superficial siderosis or vasogenic oedema, or other findings, which are suggestive of cerebral amyloid angiopathy (CAA) (see Precautions).
Treatment with lecanemab should not be initiated in patients receiving ongoing anticoagulant therapy (see Precautions).
Continue with Google